199 related articles for article (PubMed ID: 38666920)
1. PARP-Targeted Radiotheranostics with Auger Electrons: An Updated Overview.
Filippi L; Urso L; Evangelista L
Curr Issues Mol Biol; 2024 Mar; 46(4):3039-3049. PubMed ID: 38666920
[TBL] [Abstract][Full Text] [Related]
2. [
Chan CY; Chen Z; Guibbal F; Dias G; Destro G; O'Neill E; Veal M; Lau D; Mosley M; Wilson TC; Gouverneur V; Cornelissen B
J Nucl Med; 2023 Dec; 64(12):1965-1971. PubMed ID: 37770109
[TBL] [Abstract][Full Text] [Related]
3. PARP-1-Targeted Auger Emitters Display High-LET Cytotoxic Properties In Vitro but Show Limited Therapeutic Utility in Solid Tumor Models of Human Neuroblastoma.
Lee H; Riad A; Martorano P; Mansfield A; Samanta M; Batra V; Mach RH; Maris JM; Pryma DA; Makvandi M
J Nucl Med; 2020 Jun; 61(6):850-856. PubMed ID: 31676730
[TBL] [Abstract][Full Text] [Related]
4. Preclinical Efficacy of a PARP-1 Targeted Auger-Emitting Radionuclide in Prostate Cancer.
Sreekumar S; Zhou D; Mpoy C; Schenk E; Scott J; Arbeit JM; Xu J; Rogers BE
Int J Mol Sci; 2023 Feb; 24(4):. PubMed ID: 36834491
[TBL] [Abstract][Full Text] [Related]
5. Preclinical studies of a PARP targeted, Meitner-Auger emitting, theranostic radiopharmaceutical for metastatic ovarian cancer.
Hoffman SLV; Mixdorf JC; Kwon O; Johnson TR; Makvandi M; Lee H; Aluicio-Sarduy E; Barnhart TE; Jeffery JJ; Patankar MS; Engle JW; Bednarz BP; Ellison PA
Nucl Med Biol; 2023; 122-123():108368. PubMed ID: 37490805
[TBL] [Abstract][Full Text] [Related]
6. Auger electrons for cancer therapy - a review.
Ku A; Facca VJ; Cai Z; Reilly RM
EJNMMI Radiopharm Chem; 2019 Oct; 4(1):27. PubMed ID: 31659527
[TBL] [Abstract][Full Text] [Related]
7. PARP-Targeted Auger Therapy in p53 Mutant Colon Cancer Xenograft Mouse Models.
Wilson T; Pirovano G; Xiao G; Samuels Z; Roberts S; Viray T; Guru N; Zanzonico P; Gollub M; Pillarsetty NVK; Reiner T; Bargonetti J
Mol Pharm; 2021 Sep; 18(9):3418-3428. PubMed ID: 34318678
[TBL] [Abstract][Full Text] [Related]
8. PARP Theranostic Auger Emitters Are Cytotoxic in BRCA Mutant Ovarian Cancer and Viable Tumors from Ovarian Cancer Patients Enable Ex-Vivo Screening of Tumor Response.
Riad A; Gitto SB; Lee H; Winters HD; Martorano PM; Hsieh CJ; Xu K; Omran DK; Powell DJ; Mach RH; Makvandi M
Molecules; 2020 Dec; 25(24):. PubMed ID: 33352773
[TBL] [Abstract][Full Text] [Related]
9. Advancements in PARP1 Targeted Nuclear Imaging and Theranostic Probes.
Ambur Sankaranarayanan R; Kossatz S; Weber W; Beheshti M; Morgenroth A; Mottaghy FM
J Clin Med; 2020 Jul; 9(7):. PubMed ID: 32640708
[TBL] [Abstract][Full Text] [Related]
10. Application of Geant4-DNA for simulating water radiolysis induced by Auger electron-emitting radionuclides.
Adjei D; Trinh ND; Mostafavi M
J Radiat Res; 2023 Mar; 64(2):369-378. PubMed ID: 36702611
[TBL] [Abstract][Full Text] [Related]
11. A High Separation Factor for
Da Silva I; Johnson TR; Mixdorf JC; Aluicio-Sarduy E; Barnhart TE; Nickles RJ; Engle JW; Ellison PA
Molecules; 2021 Dec; 26(24):. PubMed ID: 34946596
[No Abstract] [Full Text] [Related]
12. Antibody-based cancer treatment with ultra-short range Auger electron-emitting radionuclides: dual receptor and DNA targeting strategies.
Karagiannis TC
Hell J Nucl Med; 2007; 10(3):155-9. PubMed ID: 18084655
[TBL] [Abstract][Full Text] [Related]
13. Targeted Brain Tumor Radiotherapy Using an Auger Emitter.
Pirovano G; Jannetti SA; Carter LM; Sadique A; Kossatz S; Guru N; Demétrio De Souza França P; Maeda M; Zeglis BM; Lewis JS; Humm JL; Reiner T
Clin Cancer Res; 2020 Jun; 26(12):2871-2881. PubMed ID: 32066626
[TBL] [Abstract][Full Text] [Related]
14. Correlation between energy deposition and molecular damage from Auger electrons: A case study of ultra-low energy (5-18 eV) electron interactions with DNA.
Rezaee M; Hunting DJ; Sanche L
Med Phys; 2014 Jul; 41(7):072502. PubMed ID: 24989405
[TBL] [Abstract][Full Text] [Related]
15. Panitumumab-DOTA-
Facca VJ; Cai Z; Gopal NEK; Reilly RM
Mol Pharm; 2022 Oct; 19(10):3652-3663. PubMed ID: 35926098
[TBL] [Abstract][Full Text] [Related]
16. Synthesis and Preclinical Evaluation of PSMA-Targeted
Santos JF; Braz MT; Raposinho P; Cleeren F; Cassells I; Leekens S; Cawthorne C; Mendes F; Fernandes C; Paulo A
Mol Pharm; 2024 Jan; 21(1):216-233. PubMed ID: 37992229
[TBL] [Abstract][Full Text] [Related]
17. Marshalling the Potential of Auger Electron Radiopharmaceutical Therapy.
Bolcaen J; Gizawy MA; Terry SYA; Paulo A; Cornelissen B; Korde A; Engle J; Radchenko V; Howell RW
J Nucl Med; 2023 Sep; 64(9):1344-1351. PubMed ID: 37591544
[TBL] [Abstract][Full Text] [Related]
18. Subcellular Targeting of Theranostic Radionuclides.
Bavelaar BM; Lee BQ; Gill MR; Falzone N; Vallis KA
Front Pharmacol; 2018; 9():996. PubMed ID: 30233374
[TBL] [Abstract][Full Text] [Related]
19. A radioiodinated rucaparib analogue as an Auger electron emitter for cancer therapy.
Destro G; Chen Z; Chan CY; Fraser C; Dias G; Mosley M; Guibbal F; Gouverneur V; Cornelissen B
Nucl Med Biol; 2023; 116-117():108312. PubMed ID: 36621256
[TBL] [Abstract][Full Text] [Related]
20. Radionuclide therapy with iodine-125 and other auger-electron-emitting radionuclides: experimental models and clinical applications.
Bodei L; Kassis AI; Adelstein SJ; Mariani G
Cancer Biother Radiopharm; 2003 Dec; 18(6):861-77. PubMed ID: 14969599
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
